27 September 2018 | News
Research shows adding Abbott's High Sensitive Troponin-I diagnostic test to doctors' existing standard of care can help more accurately determine a person's chances of a heart attack or other cardiac event potentially months to years in advance
Cardiovascular diseases are the leading cause of death globally. Yet unlike other conditions, heart disease can be prevented if identified early and managed through lifestyle changes and medication as needed.
To help people take control of their heart health, Abbott announced that its High Sensitive Troponin-I blood test is the first troponin test with CE Mark that can more accurately predict the chances of having a heart attack or other cardiac event potentially months to years in advance in people who otherwise appear healthy.
This life-changing technology has the potential to transform how doctors identify those at risk for developing heart disease because the diagnostic test uses a biomarker specific to the heart.
European guidelines currently recommend that doctors look at indirect heart health factors, such as a person's cholesterol levels, blood pressure as well as if they have diabetes or are a smoker, to determine risk for developing heart disease.
A substantial body of research has shown that measuring a person's troponin levels using Abbott's High Sensitive Troponin-I test provides better predictive information for determining a person's chances of developing future heart disease when added to the current standard of care.